Model List of Essential Medicines

Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + dolutegravir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Aciclovir

Section	Indications
Antiherpes medicines ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium) ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet ◦ Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium diihydrate); 25 mg per mL in vial solution for infusion (as sodium)	Zoster Herpes simplex infections Varicella

Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg	Chronic hepatitis C

Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 250 mg tablet	Chronic hepatitis C

Didanosine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution ◦ Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors ◦ Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors ◦ Oral > Solid: 600 mg tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 50 mg + 100 mg	Chronic hepatitis C

Emtricitabine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 10 mg per mL ◦ Oral > Solid: 200 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 25 mg + 25 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Emtricitabine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 0.05 mg per mL ◦ Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 50 mg + 20 mg granules ◦ Oral > Solid > tablet: 100 mg + 40 mg	Chronic hepatitis C

Indinavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 400 mg (as sulfate)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section	Indications
Medicines for prevention of HIV-related opportunistic infections ◦ Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)	Other specified prophylactic measures

Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid: 150 mg tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals ◦ Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

Lopinavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable) ◦ Oral > Solid > dosage form: 40 mg + 10 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 250 mg (as mesilate) ◦ Oral > Other: 50 mg per g oral powder	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid > dispersible tablet: 50 mg ◦ Oral > Solid > tablet: 200 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

Oseltamivir

Section	Indications
Other antivirals ◦ Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid ◦ Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)	Influenza due to identified seasonal influenza virus

Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors ◦ Oral > Liquid: 100 mg granules for oral suspension ◦ Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Ribavirin

Section	Indications
Other antivirals ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Viral haemorrhagic fever, not elsewhere classified
Medicines for hepatitis C > Other antivirals for hepatitis C ◦ Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution ◦ Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

Ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors ◦ Oral > Solid: 200 mg; 500 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations ◦ Oral > Solid: 150 mg	Chronic hepatitis C

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg; 400 mg ◦ Oral > Solid > granules: 200 mg in sachet	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations ◦ Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg ◦ Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet	Chronic hepatitis C

Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Liquid: 5 mg per 5 mL powder for oral solution ◦ Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified

Tenofovir alafenamide

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 25 mg	Chronic hepatitis B

Tenofovir disoproxil fumarate

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Contact with or exposure to human immunodeficiency virus Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)	Chronic hepatitis B

Valganciclovir

Section	Indications
Other antivirals ◦ Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution ◦ Oral > Solid > tablet: 450 mg (as hydrochloride)	Cytomegaloviral retinitis

Zidovudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors ◦ Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion ◦ Oral > Liquid: 50 mg per 5 mL ◦ Oral > Solid > tablet: 300 mg ◦ Oral > Solid > capsule: 250 mg	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified